FDA Grants Dual Approval to Trastuzumab Deruxtecan in Early-Stage HER2-Positive Breast Cancer, Extending ADC Dominance 9 hours ago AnaIn Breaking NewsClinical TrialsTop Stories
Shionogi’s Ensitrelvir Becomes First Oral Antiviral Approved for Post-Exposure COVID-19 Prevention 14 hours ago AnaIn Clinical TrialsPharma Industry UpdatesResearch Updates
Tortugas Neuroscience Launches with $106 Million to Advance Four Clinical-Stage CNS Programs Licensed from Eisai and Hansoh 19 hours ago AnaIn DealsFunding RoundsResearch UpdatesTop Stories
BioMarin Reports Positive Phase 3 Data for VOXZOGO in Hypochondroplasia 1 day ago AnaIn Biopharma HighlightsBreaking NewsClinical TrialsTop Stories
FDA Approves VEPPANU (Vepdegestrant), First Oral PROTAC Therapy for ESR1-Mutated Breast Cancer 2 days ago AnaIn Biopharma HighlightsBreaking NewsResearch Updates
Alzheimer’s Drug Pipeline Reaches Record Scale in 2026 With 192 Active Trials 2 days ago AnaIn Breaking NewsResearch UpdatesTop Stories
Biotech M&A Reaches $106 Billion in 2026 as Pharma Giants Race to Fill Pipelines 3 days ago AnaIn Breaking NewsBreakthroughsTop StoriesVenture Capital
Early Alzheimer’s Egg-Shell Protein Therapy Shows Promise in Small Human Study 9 months ago AnaIn Clinical TrialsStartups
Ultragenyx Gene Therapy Rejected by FDA Even as Takeda Scores Big in Narcolepsy Trial 11 months ago AnaIn Clinical TrialsFDA Approvals
1 FDA Grants Dual Approval to Trastuzumab Deruxtecan in Early-Stage HER2-Positive Breast Cancer, Extending ADC Dominance
3 Tortugas Neuroscience Launches with $106 Million to Advance Four Clinical-Stage CNS Programs Licensed from Eisai and Hansoh
